Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

244 11 Hybrid Cell Vaccination for Cancer Immune Therapy
42 Bakker AB, Schreurs MW, de Boer AJ,
Kawakami Y, Rosenberg SA, Adema GJ,
Figdor CG. Melanocyte lineage-specific
antigen gp100 is recognized by melanoma-derived
tumor-infiltrating lymphocytes.
J Exp Med 1994; 179: 1005±9.
43 Wolfel T,Van Pel A, Brichard V,
Schneider J, Seliger B, Meyer zum
Buschenfelde KH, Boon T. Two tyrosinase
nonapeptides recognized on
HLA-A2 melanomas by autologous cytolytic
T lymphocytes. Eur J Immunol
1994; 24: 759±64.
44 Valmori D, Gervois N, Rimoldi D,
Fonteneau JF, Bonelo A, Lienard D,
Rivoltini L, Jotereau F, Cerottini JC,
Romero P. Diversity of the fine specificity
displayed by HLA-A*0201-restricted
CTL specific for the immunodominant
Melan-A/MART-1 antigenic peptide.
J Immunol 1998; 161: 6956±62.
45 Skipper JC, Kittlesen DJ, Hendrickson
RC, Deacon DD, Harthun NL,
Wagner SN, Hunt DF, Engelhard
VH, Slingluff CL Jr. Shared epitopes
for HLA-A3-restricted melanomareactive
human CTL include a naturally
processed epitope from Pmel-17/gp100.
J Immunol 1996; 157: 5027±33.
46 Kawashima I, Tsai V, Southwood S,
Takesako K, Sette A, Celis E. Identification
of HLA-A3-restricted cytotoxic T
lymphocyte epitopes from carcinoembryonic
antigen and HER-2/neu by primary
in vitro immunization with peptide-pulsed
dendritic cells. Cancer Res
1999; 59: 431±5.
47 Tsang KY, Zaremba S, Nieroda CA,
Zhu MZ, Hamilton JM, Schlom J.
Generation of human cytotoxic T cells
specific for human carcinoembryonic
antigen epitopes from patients immunized
with recombinant vaccinia±CEA
vaccine. J Natl Cancer Inst 1995; 87:
982±90.
48 Romero P, Pannetier C, Herman J,
Jongeneel CV, Cerottini JC,
Coulie PG. Multiple specificities in the
repertoire of a melanoma patient's cytolytic
T lymphocytes directed against tumor
antigen MAGE-1.A1. J Exp Med
1995; 182: 1019±28.
49 Boel P,Wildmann C, Sensi ML,
Brasseur R, Renauld JC, Coulie P,
Boon T, van der Bruggen P. BAGE: a
new gene encoding an antigen recognized
on human melanomas by cytolytic
T lymphocytes. Immunity 1995; 2:
167±75.
50 Tanzarella S, Russo V, Lionello I,
Dalerba P, Rigatti D, Bordignon C,
Traversari C. Identification of a promiscuous
T-cell epitope encoded by
multiple members of the MAGE family.
Cancer Res 1999; 59: 2668±74.
51 Fisk B, Blevins TL,Wharton JT, Ioannides
CG. Identification of an immunodominant
peptide of HER-2/neu protooncogene
recognized by ovarian tumor-specific
cytotoxic T lymphocyte
lines. J Exp Med 1995; 181: 2109±17.
52 Peoples GE, Goedegebuure PS,
Smith R, Linehan DC,Yoshino I,
Eberlein TJ. Breast and ovarian cancer-specific
cytotoxic T lymphocytes recognize
the same HER2/neu-derived
peptide. Proc Natl Acad Sci USA 1995;
92: 432±6.
53 Kono K, Rongcun Y, Charo J, Ichihara
F, Celis E, Sette A, Appella E,
Sekikawa T, Matsumoto Y, Kiessling
R. Identification of HER2/neu-derived
peptide epitopes recognized by
gastric cancer-specific cytotoxic T lymphocytes.
Int J Cancer 1998; 78: 202±8.
54 Rongcun Y, Salazar-Onfray F,
Charo J, Malmberg KJ, Evrin K,
Maes H, Kono K, Hising C, Petersson
M, Larsson O, Lan L, Appella E,
Sette A, Celis E, Kiessling R. Identification
of new HER2/neu-derived peptide
epitopes that can elicit specific CTL
against autologous and allogeneic carcinomas
and melanomas. J Immunol
1999; 163: 1037±44.
55 Coulie PG, Lehmann F, Lethe B,
Herman J, Lurquin C, Andrawiss M,
Boon T. A mutated intron sequence
codes for an antigenic peptide recognized
by cytolytic T lymphocytes on a
human melanoma. Proc Natl Acad Sci
USA 1995; 92: 7976±80.
56 Wolfel T, Hauer M, Schneider J,
Serrano M,Wolfel C, Klehmann-
Hieb E, De Plaen E, Hankeln T,
Meyer zum Buschenfelde KH,
Beach D. A p16INK4a-insensitive
CDK4 mutant targeted by cytolytic T